Integra LifeSciences is emerging from a period of operational disruption, with Q2 2026 showing a return to positive net income of $4.5M and a 52.5% gross margin, though revenue growth remains muted at 0.8% YoY. The company's turnaround is supported by improved...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.56+16.5% vs $0.48 | $419M+0.3% vs $418M |
Q2 2026 May 5, 2026 | $0.54+31.7% vs $0.41 | $392M+2.6% vs $382M |
Q1 2026 Feb 26, 2026 | $0.83+5.1% vs $0.79 | $435M+1.2% vs $430M |
Q4 2025 Oct 30, 2025 | $0.54+25.6% vs $0.43 | $402M-6.4% vs $430M |
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Integra sees steady Specialty Surgery demand and improving efficiency, but leverage and currency swings remain key challenges for Integra.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients
Benchmark IART against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Integra LifeSciences Holdings Corporation (IART)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.68 | $986.16M | -1.88 | 1.53% | -31.58% | -39.9% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $14.94 | $1.73B | -12.25 | 8.28% | -21.25% | -44% | — | |
| $55.14 | $2.8B | -229.75 | 14.88% | 1.85% | 2.14% | — | |
| $410.35 | $58.77B | -269.97 | 35.9% | -7.11% | -11.73% | — | |
| $85.37 | $5.09B | 40.08 | 11.66% | 9.22% | 9.07% | — |
Integra LifeSciences Holdings Corporation (IART) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Integra LifeSciences Holdings Corporation (IART) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
May 8, 2026·SEC
May 5, 2026·SEC
Get notified when IART posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Integra LifeSciences Holdings Corporation (IART) stock FAQ — growth, dividends, profitability & financials explained
Integra LifeSciences Holdings Corporation (IART) reported $1.65B in revenue for fiscal year 2025. This represents a 12478% increase from $13.1M in 1996.
Integra LifeSciences Holdings Corporation (IART) grew revenue by 1.5% over the past year. Growth has been modest.
Integra LifeSciences Holdings Corporation (IART) reported a net loss of $7.2M for fiscal year 2025.
Integra LifeSciences Holdings Corporation (IART) has a return on equity (ROE) of -39.9%. Negative ROE indicates the company is unprofitable.
Integra LifeSciences Holdings Corporation (IART) generated $38.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
